Arcturus Therapeutics Holdings (ARCT) Net Cash Flow (2018 - 2025)
Historic Net Cash Flow for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$16.1 million.
- Arcturus Therapeutics Holdings' Net Cash Flow rose 3042.63% to -$16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$56.8 million, marking a year-over-year increase of 2423.05%. This contributed to the annual value of -$55.0 million for FY2024, which is 2193.54% down from last year.
- Latest data reveals that Arcturus Therapeutics Holdings reported Net Cash Flow of -$16.1 million as of Q3 2025, which was up 3042.63% from -$20.5 million recorded in Q2 2025.
- Arcturus Therapeutics Holdings' Net Cash Flow's 5-year high stood at $154.2 million during Q4 2022, with a 5-year trough of -$63.9 million in Q1 2023.
- For the 5-year period, Arcturus Therapeutics Holdings' Net Cash Flow averaged around -$11.9 million, with its median value being -$20.2 million (2023).
- Examining YoY changes over the last 5 years, Arcturus Therapeutics Holdings' Net Cash Flow showed a top increase of 45546.85% in 2022 and a maximum decrease of 138838.74% in 2022.
- Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Net Cash Flow stood at -$43.4 million in 2021, then skyrocketed by 455.47% to $154.2 million in 2022, then plummeted by 113.07% to -$20.2 million in 2023, then soared by 99.26% to -$150000.0 in 2024, then plummeted by 10638.0% to -$16.1 million in 2025.
- Its Net Cash Flow stands at -$16.1 million for Q3 2025, versus -$20.5 million for Q2 2025 and -$20.1 million for Q1 2025.